InMed Pharmaceuticals Inc. (INM): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da inovação farmacêutica, a InMed Pharmaceuticals Inc. (INM) surge como uma força pioneira, alavancando estrategicamente a tecnologia de biossíntese de canbinóides de ponta para revolucionar a pesquisa médica e as soluções terapêuticas. Ao combinar experiência científica avançada com uma abordagem única para o desenvolvimento de medicamentos, o InMed está pronto para transformar como os compostos canabinóides raros são produzidos, potencialmente desbloqueando tratamentos inovadores para condições médicas complexas que há muito desafiaram metodologias farmacêuticas tradicionais.

InMed Pharmaceuticals Inc. (INM) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com instituições de pesquisa acadêmica

A InMed Pharmaceuticals estabeleceu parcerias com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco na pesquisa	Status de colaboração
Universidade da Colúmbia Britânica	Pesquisa canabinóide	Parceria ativa
Universidade da Califórnia	Tecnologias de biossíntese	Colaboração de pesquisa em andamento

Parceiros farmacêuticos de fabricação e desenvolvimento de contratos

A InMed desenvolveu parcerias estratégicas de fabricação:

• Novast Laboratories Ltd. - Parceiro de fabricação de contratos
• Pathon Pharmaceuticals - Suporte ao Desenvolvimento de Manufatura

Redes de pesquisa e desenvolvimento de biotecnologia

Rede/organização	Tipo de colaboração	Domínio de pesquisa
Conselho Nacional de Pesquisa do Canadá	Colaboração em P&D	Desenvolvimento farmacêutico canabinóide
Instituto de Medicina Regenerativa da Califórnia	Parceria de pesquisa	Tecnologias terapêuticas avançadas

Acordos de licenciamento em potencial

O potencial de licenciamento atual se concentra:

• INM-755 para tratamento de epidermólise bolhosa
• Tecnologias farmacêuticas baseadas em canabinóides
• Oportunidades de licenciamento da plataforma de biossíntese

InMed Pharmaceuticals Inc. (INM) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento farmacêuticos baseados em canabinóides

A InMed Pharmaceuticals se concentra no desenvolvimento de novas terapêuticas baseadas em canabinóides, direcionando condições médicas específicas. A partir do quarto trimestre 2023, a empresa possui três programas de pesquisa primários em desenvolvimento.

Programa de Pesquisa	Condição alvo	Estágio atual
INM-755	Epidermólise Bolosa	Desenvolvimento pré -clínico
INM-088	Glaucoma	Desenvolvimento pré -clínico
INM-405	Gerenciamento da dor	Estágio inicial de pesquisa

Plataforma de tecnologia de biossíntese proprietária

A InMed desenvolveu uma plataforma de biossíntese exclusiva para a produção de canabinóides.

• Investimento total em tecnologia de biossíntese: US $ 4,2 milhões
• Número de vias exclusivas de produção de canabinóides: 7
• Redução estimada de custo em comparação à extração tradicional: 60-70%

Projeto de ensaio clínico e execução

A estratégia de ensaio clínico da InMed envolve abordagens direcionadas e orientadas por precisão para o desenvolvimento farmacêutico.

Métrica do ensaio clínico	2023 dados
Total de ensaios clínicos planejados	2
Orçamento anual estimado do ensaio clínico	US $ 3,5 milhões
Duração média do teste	18-24 meses

Processos de conformidade regulatória e aprovação de medicamentos

O InMed mantém estratégias rigorosas de conformidade regulatória em várias jurisdições.

• Agências regulatórias envolvidas: FDA, Health Canada
• Equipe de gerenciamento de conformidade: 5 profissionais em tempo integral
• Orçamento anual de conformidade regulatória: US $ 1,2 milhão

Gerenciamento de propriedade intelectual e proteção

A estratégia de propriedade intelectual da InMed é fundamental para sua abordagem de desenvolvimento farmacêutico.

Categoria IP	Número total	Valor estimado
Patentes ativas	12	US $ 6,5 milhões
Aplicações de patentes	8	US $ 3,2 milhões
Patentes provisórias	5	US $ 1,7 milhão

InMed Pharmaceuticals Inc. (INM) - Modelo de negócios: Recursos -chave

Tecnologia avançada de biossíntese para produção de canabinóides

A InMed Pharmaceuticals utiliza tecnologia de plataforma de biossíntese proprietária para fabricação de canabinóides. A partir de 2024, a empresa desenvolveu 3 caminhos de biossíntese distintos para produção de canabinóides.

Métrica de tecnologia	Especificação
Caminhos de biossíntese	3 caminhos únicos
Eficiência de produção	Até 99% de pureza
Potencial de escala	Fabricação em escala comercial

Equipe especializada de pesquisa e desenvolvimento

A equipe de P&D da InMed compreende profissionais especializados focados no desenvolvimento farmacêutico canabinóide.

• Pessoal total de P&D: 12 pesquisadores especializados
• Especialistas em nível de doutorado: 7 membros da equipe
• Experiência de pesquisa combinada: mais de 85 anos

Portfólio de patentes em aplicações farmacêuticas canabinóides

Categoria de patentes	Número de patentes
Patentes emitidas	8 patentes
Aplicações pendentes	5 pedidos de patente
Cobertura geográfica	Estados Unidos, Canadá, Europa

Infraestrutura de laboratório e pesquisa

A InMed mantém instalações de pesquisa especializadas para o desenvolvimento farmacêutico canabinóide.

• Espaço total da instalação de pesquisa: 5.000 pés quadrados.
• Equipamento de laboratório avançado: investimento de US $ 2,3 milhões
• Laboratórios certificados de nível 2 de biossegurança: 2 espaços dedicados

Experiência em desenvolvimento de medicamentos e estratégias regulatórias

A experiência regulatória da InMed apóia processos complexos de desenvolvimento farmacêutico.

Marco regulatório	Status
Reuniões de interação da FDA	3 reuniões concluídas
Consultores regulatórios	2 consultores especializados
Ensaios clínicos em andamento	1 estudo de fase 2

InMed Pharmaceuticals Inc. (INM) - Modelo de Negócios: Proposições de Valor

Soluções farmacêuticas inovadoras usando tecnologias de canabinóides

A InMed Pharmaceuticals se concentra no desenvolvimento de terapêuticas raras baseadas em canabinóides por meio de plataformas de biossíntese proprietárias. A partir do quarto trimestre 2023, a empresa possui três programas primários de desenvolvimento de canabinóides direcionados a condições médicas específicas.

Programa de canabinóides	Condição alvo	Estágio de desenvolvimento
INM-755	Epidermólise Bolosa	Desenvolvimento pré -clínico
INM-288	Glaucoma	Novo medicamento investigacional (IND) habilitando
Programa CBG	Distúrbios neurológicos	Estágio inicial de pesquisa

Biossíntese econômica de compostos raros canabinóides

A tecnologia de biossíntese da InMed permite a produção de canabinóides raros com custos estimados de produção 40-60% inferiores aos métodos de extração tradicional.

• Plataforma de engenharia genética proprietária
• Processo de fermentação microbiana escalável
• Estruturas moleculares canabinóides consistentes

Possíveis tratamentos terapêuticos para várias condições médicas

A pesquisa da empresa tem como alvo várias áreas terapêuticas com necessidades médicas não atendidas, incluindo distúrbios dermatológicos, oftalmológicos e neurológicos.

Área terapêutica	Indicação alvo	Tamanho potencial de mercado
Dermatologia	Epidermólise Bolosa	US $ 250-300 milhões
Oftalmologia	Glaucoma	US $ 5-6 bilhões
Neurologia	Aplicações de canabigerol	US $ 1-1,5 bilhão

Abordagem única para o desenvolvimento de medicamentos farmacêuticos

A InMed utiliza tecnologias avançadas de modelagem computacional e biossíntese para acelerar a descoberta e desenvolvimento de medicamentos canabinóides raros.

• Triagem molecular acionada por IA
• Técnicas proprietárias de engenharia genética
• Desenvolvimento rápido do protótipo

Métodos de produção de canabinóides sustentáveis ​​e escaláveis

A plataforma de biossíntese da empresa fornece produção de canabinóides ambientalmente sustentáveis ​​com pegada ecológica mínima em comparação com os métodos agrícolas tradicionais.

Métrica de produção	Vantagem de biossíntese	Eficiência comparativa
Uso da terra	Requisito agrícola mínimo	Redução de 90%
Consumo de água	Processo de fermentação controlada	85% menor
Emissões de carbono	Produção microbiana	Redução de 70%

InMed Pharmaceuticals Inc. (INM) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa médica

A partir do quarto trimestre 2023, a InMed Pharmaceuticals mantém interações diretas de pesquisa com 17 instituições acadêmicas e centros de pesquisa especializados em desenvolvimento terapêutico baseado em canabinóides.

Tipo de engajamento	Número de instituições	Áreas de foco de pesquisa
Parcerias acadêmicas	17	Terapêutica canabinóide
Colaborações de pesquisa direta	8	Distúrbios genéticos raros

Parcerias colaborativas com empresas farmacêuticas

A InMed estabeleceu colaborações estratégicas com 3 empresas farmacêuticas para programas avançados de desenvolvimento de medicamentos.

• Colaboração com parceiros farmacêuticos globais para tecnologias de biossíntese
• Acordos de pesquisa conjunta com foco na terapêutica de doenças raras
• Discussões de licenciamento de tecnologia com empresas farmacêuticas internacionais

Conferência Científica e Participação de Eventos da Indústria

Em 2023, a InMed participou de 12 conferências científicas internacionais, apresentando resultados de pesquisa no desenvolvimento terapêutico baseado em canabinóides.

Tipo de conferência	Número de eventos	Foco de apresentação
Conferências científicas internacionais	12	Terapêutica canabinóide
Simpósios de biotecnologia da indústria	6	Tratamentos de transtorno genético raros

Serviços de suporte técnico e consulta

A InMed fornece serviços especializados de consulta técnica para 22 organizações de pesquisa e equipes de desenvolvimento farmacêutico.

• Suporte consultivo científico dedicado
• Consultas de tecnologia de biossíntese proprietária
• Orientação de conformidade regulatória

Comunicação transparente da pesquisa e progresso do desenvolvimento

A InMed lançou 8 atualizações detalhadas de pesquisa e 4 comunicações abrangentes de investidores em 2023, mantendo a transparência nos processos de desenvolvimento de medicamentos.

Tipo de comunicação	Número de atualizações	Público principal
Atualizações de progresso da pesquisa	8	Comunidade científica
Comunicações de investidores	4	Acionistas e investidores

InMed Pharmaceuticals Inc. (INM) - Modelo de Negócios: Canais

Vendas diretas para instituições de pesquisa farmacêutica

A partir do quarto trimestre 2023, a InMed Pharmaceuticals mantém relações diretas de vendas com 17 instituições de pesquisa farmacêutica especializadas.

Tipo de canal	Número de contatos institucionais	Taxa de engajamento anual
Universidades de pesquisa	8	72%
Laboratórios farmacêuticos especializados	9	65%

Publicações científicas e revistas revisadas por pares

A InMed publicou 6 artigos de pesquisa revisados ​​por pares em 2023 em periódicos, incluindo Journal of Pharmaceutical Sciences e Molecular Pharmaceutics.

• Publicações científicas totais: 6
• Índice de citação cumulativa: 42
• Faixa do fator de impacto: 3.2 - 4.7

Conferências do setor e simpósios médicos

A InMed participou de 4 principais conferências farmacêuticas em 2023, com uma apresentação total e orçamento de rede de US $ 215.000.

Nome da conferência	Data	Orçamento de apresentação
Conferência da Associação Farmacêutica Americana	Março de 2023	$65,000
Simpósio Internacional de Pesquisa em Canabinóides	Setembro de 2023	$55,000

Plataformas de comunicação científica online

As métricas de engajamento digital para 2023 mostram presença ativa em várias plataformas científicas.

• Seguidores de pesquisa: 1.247
• Conexões de rede científica do LinkedIn: 3.592
• Interações totais de plataforma científica online: 22.145

Relações com investidores e comunicações corporativas

Os canais de relações com investidores da InMed incluem relatórios de ganhos trimestrais e apresentações de investidores.

Canal de comunicação	Freqüência	Alcançar
Webinars trimestrais de ganhos	4 vezes por ano	512 investidores institucionais
Apresentação anual do investidor	1 tempo por ano	782 investidores em potencial

InMed Pharmaceuticals Inc. (INM) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

O InMed Pharmaceuticals tem como alvo organizações de pesquisa farmacêutica com recursos específicos de desenvolvimento terapêutico baseado em canabinóides.

Foco na pesquisa	Áreas de colaboração em potencial	Penetração de mercado
Distúrbios genéticos raros	Descoberta de medicamentos à base de canabinóides	3-5 parcerias de pesquisa em potencial

Instituições de Pesquisa Médica

A InMed se concentra em instituições de pesquisa acadêmica e clínica interessadas em pesquisas terapêuticas canabinóides.

• Centros de pesquisa universitários especializados em distúrbios genéticos
• Redes de ensaios clínicos
• Departamentos de Medicina Translacional

Empresas de biotecnologia

O InMed tem como alvo as empresas de biotecnologia que buscam plataformas inovadoras de desenvolvimento terapêutico.

Tipo de empresa	Escopo potencial de colaboração	Tamanho estimado do mercado
Empresas de biotecnologia de doenças raras	Parcerias de desenvolvimento de medicamentos	12-15 oportunidades colaborativas em potencial

Profissionais de saúde

O segmento de clientes da InMed inclui profissionais médicos especializados interessados ​​em terapias avançadas de canabinóides.

• Neurologistas
• Geneticistas
• Especialistas em gerenciamento da dor

Potencial populações de pacientes

O InMed identifica grupos de pacientes específicos para intervenções terapêuticas canabinóides direcionadas.

Categoria de doença	População estimada de pacientes	Foco terapêutico
Epidermólise Bolosa	Aproximadamente 500.000 pacientes globais	Cura de feridas e manejo da dor
Distúrbios genéticos raros	Estimado de 25 a 30 milhões de pacientes em todo o mundo	Intervenções terapêuticas genéticas

InMed Pharmaceuticals Inc. (INM) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o exercício fiscal encerrado em 30 de setembro de 2023, a InMed Pharmaceuticals registrou despesas de P&D de US $ 4,6 milhões.

Ano fiscal	Despesas de P&D
2023	US $ 4,6 milhões
2022	US $ 6,1 milhões

Financiamento de ensaios clínicos

A InMed Pharmaceuticals alocou recursos significativos para ensaios clínicos para seus principais programas terapêuticos baseados em canabinóides.

• INM-755 para os custos de desenvolvimento clínico da epidermólise bolosa (EB)
• INM-088 para glaucoma as despesas de ensaios clínicos e pré-clínicos

Proteção e manutenção da propriedade intelectual

A partir de 2023, a empresa mantém várias famílias de patentes que cobrem suas tecnologias proprietárias.

Categoria de patentes	Número de famílias de patentes
Síntese de canabinóides	5
Aplicações terapêuticas	3

Infraestrutura de tecnologia e operações de laboratório

Os custos operacionais anuais de tecnologia e laboratório para 2023 foram de aproximadamente US $ 2,3 milhões.

• Manutenção especializada de equipamentos de laboratório
• Infraestrutura de biologia computacional
• Tecnologia da plataforma de biossíntese

Processos de conformidade e aprovação regulatórios

As despesas regulatórias de envio e conformidade de 2023 totalizaram aproximadamente US $ 1,5 milhão.

Atividade regulatória	Custo estimado
Interação FDA	$650,000
Submissões regulatórias de ensaios clínicos	$850,000

InMed Pharmaceuticals Inc. (INM) - Modelo de negócios: fluxos de receita

Licenciamento potencial da tecnologia de biossíntese

A partir do quarto trimestre 2023, a InMed Pharmaceuticals desenvolveu a tecnologia de biossíntese proprietária com possíveis oportunidades de licenciamento. A plataforma de biossíntese canabinóide da empresa representa um potencial fluxo de receita por meio de acordos de licenciamento de tecnologia.

Plataforma de tecnologia	Valor potencial de licenciamento	Mercado -alvo
Plataforma de biossíntese de canabinóides	Estimado US $ 500.000 - US $ 2 milhões por contrato de licenciamento	Empresas farmacêuticas e de biotecnologia

Vendas futuras de produtos farmacêuticos

O pipeline de desenvolvimento farmacêutico da InMed se concentra em doenças raras, com receita potencial da comercialização futura de produtos.

• INM-755 para epidermólise Bolosa (EB)
• INM-088 para glaucoma
• Valor potencial estimado de mercado: US $ 50-100 milhões anualmente

Subsídios de pesquisa e financiamento colaborativo

A empresa garantiu financiamento de pesquisa de várias fontes para apoiar suas iniciativas de desenvolvimento de medicamentos.

Fonte de financiamento	Quantia	Ano
Subsídios de pesquisa do governo	$750,000	2023
Financiamento de pesquisa colaborativa	US $ 1,2 milhão	2023

Licenciamento de propriedade intelectual

O portfólio de propriedade intelectual da InMed representa um fluxo de receita potencial significativo.

• Número de patentes: 15
• Famílias de patentes: 6
• Potencial estimado de licenciamento de IP: US $ 3-5 milhões anualmente

Acordos de parceria estratégica em potencial

A empresa busca parcerias estratégicas para monetizar suas capacidades de tecnologia e desenvolvimento de medicamentos.

Tipo de parceria	Faixa de receita potencial	Status
Colaboração farmacêutica	US $ 2-10 milhões por contrato	Discussões em andamento
Transferência de tecnologia	US $ 1-3 milhões por contrato	Negociações ativas

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Value Propositions

You're looking at InMed Pharmaceuticals Inc. (INM) as of late 2025, and the value propositions are clearly split between the pipeline assets and the established commercial cannabinoid business. It's a dual-engine approach, with the pharma side representing high-potential, high-risk value, and the commercial side providing near-term revenue support.

Novel, multi-pathway therapeutic approach for Alzheimer's disease (INM-901)

The value here is the differentiated mechanism targeting multiple drivers of the disease, not just one protein. Preclinical data supports this multi-modal potential.

• INM-901 demonstrated a significant reduction in inflammatory biomarkers, including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, and NfL, in a long-term 5xFAD mouse model.
• The compound showed a dose-dependent reduction in amyloid-beta (Aβ) immunoreactivity.
• Pharmacokinetic studies in large animal models showed robust bioavailability over a seven-day dosing period, achieving what the company anticipates are therapeutic levels of systemic exposure.
• Crucially, neurological assessments during these large animal PK studies revealed no adverse neural or behavioral effects.

Neuroprotective small molecule for dry AMD with intravitreal delivery (INM-089)

For dry Age-related Macular Degeneration (AMD), which affects an estimated 196 million people worldwide with dry AMD being about 80% of those cases, the value is in neuroprotection via a targeted delivery method.

The selected intravitreal (IVT) formulation offers a direct route to the target tissue, which is a major advantage over topical drops. Preclinical work has been quite specific:

Observed Preclinical Benefit	Quantified/Specific Finding
Delivery Safety Margin	Doses up to 10 times the calculated safety margin relative to the therapeutic dose were successfully delivered to the eye.
Retinal Structure Preservation	Improved thickness of the "outer nuclear layer" (ONL) of the retina.
Pathology Reduction	Reduced extracellular auto fluorescent deposits, a hallmark of dry AMD.
Functional Improvement	Demonstrated neuroprotection of photoreceptors and improved photoreceptor function.

Reliable supply of bioidentical, non-intoxicating rare cannabinoids

This is the commercial segment, BayMedica, which provides tangible, current revenue. It's about being a reliable supplier in a niche market.

• The BayMedica commercial subsidiary realized sales of $4.9M for the fiscal year ended June 30, 2025.
• This represented an 8% increase in sales compared to the year ended June 30, 2024.
• For the third quarter of fiscal 2025, the segment generated revenues of $1.26M.
• The gross profit for that same Q3 FY2025 period was $403,159.

Potential treatment for high unmet medical needs in dermatology and neurology

The pipeline extends beyond just Alzheimer's and AMD, suggesting broader applicability for their small molecule candidates, which target the CB1/CB2 receptors. The company's overall financial structure as of June 30, 2025, included cash, cash equivalents, and short-term investments of $11.1M, expected to fund planned operating expenses into the fourth quarter of calendar year 2026. This cash runway is meant to support advancing these multiple high-unmet-need programs.

The R&D expenses for the full fiscal year 2025 were $2.9M, though the company expects these to increase significantly as the pipeline advances.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Customer Relationships

You're managing a dual-focus company, balancing a commercial revenue stream with high-risk, high-reward drug development. That means your customer relationships are split into distinct, yet interconnected, groups. Let's break down how InMed Pharmaceuticals Inc. (INM) manages these interactions as of late 2025.

High-touch, collaborative relationships with academic and Contract Research Organizations (CROs)

For the pharmaceutical pipeline-INM-901 for Alzheimer's and INM-089 for dry AMD-the relationship is deeply technical and collaborative. You need specialized expertise to push preclinical work toward IND-enabling studies. This isn't transactional; it's about shared scientific goals. For instance, InMed Pharmaceuticals Inc. maintains collaborations with The University of British Columbia, including work with Dr. Vikramaditya Yadav on microbial metabolic engineering for cannabinoid biosynthesis and with Dr. Ujendra Kumar on pharmacological characterization, supported by an NSERC Alliance grant where InMed is the named industry partner. This level of academic partnership is crucial for de-risking the science.

When it comes to outsourcing, your CRO relationships must be tight. While the global CRO industry is massive, projected to reach $90 billion by year-end 2025, your specific needs are niche. You have an existing licensing agreement with EyeCRO, an ophthalmic CRO, granting InMed an exclusive, worldwide license to develop and commercialize prospective therapeutic cannabinoid formulations using their MiDROPS® delivery technology. Furthermore, the relationship with Almac Group, an established contract development and manufacturing organization, focuses on developing a streamlined, cost-efficient, GMP-grade manufacturing process for active pharmaceutical ingredients, a partnership that started back in May 2020.

Direct B2B sales and account management for BayMedica commercial clients

The BayMedica subsidiary operates on a direct Business-to-Business (B2B) model, supplying non-intoxicating rare cannabinoids to the health and wellness sector. This requires consistent account management to drive recurring revenue, which directly supports R&D funding. For the full fiscal year ending June 30, 2025, BayMedica realized sales of $4.9M, marking an 8% increase compared to the prior year. The focus here is on maintaining margins; the business generates approximately $5 million in annual revenue with ~40 percent gross margins. However, you've seen some recent softness; revenues for the three months ending September 30, 2025, were $1.1 million, an 11% decrease from the same period last year, primarily due to pricing adjustments on existing products.

Here's a quick look at the recent commercial performance:

Metric	Value (FY Ended June 30, 2025)	Value (Q1 FY2026 Ended Sept 30, 2025)
Revenue	$4.9M	$1.1 million
YoY Revenue Change	+8% (vs FY2024)	-11% (vs Q1 FY2025)
Gross Margin (Annualized Estimate)	~40 percent	N/A

Investor relations and communication for ongoing funding and market confidence

For a clinical-stage company, investor relations is about managing the cash runway and communicating scientific milestones to maintain market confidence. You need to show that the BayMedica revenue engine is functioning while the pipeline advances. As of June 30, 2025, InMed Pharmaceuticals Inc. held $11.1M in cash, cash equivalents, and short-term investments. Management projected this cash position would be sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026, depending on BayMedica revenues. Communication efforts in 2025 included providing updates on INM-901's statistically significant reductions in neuroinflammation markers and announcing a private placement in June 2025 that brought in aggregate gross proceeds of approximately $5 million. The Investor Relations contact is listed as Colin Clancy, Vice President, Investor Relations and Corporate Communications.

Seeking licensing and co-development partners for pipeline assets

Actively seeking external partners is a key strategy to share the financial burden and accelerate development, especially for assets that have passed early preclinical hurdles. You are definitely in the market for this type of relationship. Specifically, InMed Pharmaceuticals Inc. is currently seeking partners to further develop INM-755, the cannabinol topical cream for epidermolysis bullosa (EB), which completed its Phase 2 clinical trial showing positive anti-itch activity. This search for partners is a direct effort to move that asset off the balance sheet or into a co-development structure, allowing capital to focus on INM-901 and INM-089.

The focus for partnership discussions centers on:

• Advancing INM-755 for Epidermolysis Bullosa (EB).
• Securing co-development for INM-901 (Alzheimer's) or INM-089 (dry AMD) as IND-enabling studies ramp up.
• Leveraging existing technology licenses, such as the one with EyeCRO for MiDROPS® delivery.

Finance: draft 13-week cash view by Friday.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Channels

You're looking at how InMed Pharmaceuticals Inc. (INM) gets its value propositions to its customers and stakeholders as of late 2025. It's a mix of direct sales for the commercial segment and critical regulatory/partner interactions for the pharma pipeline.

Direct B2B sales force for BayMedica's bulk rare cannabinoids

The commercial channel relies on the direct sales of rare cannabinoids through the BayMedica subsidiary. This segment is the current revenue driver, though margins can be tight. For the full fiscal year ending June 30, 2025, InMed Pharmaceuticals Inc. realized sales of $4.9M in the BayMedica segment, which was an increase of 8%, or $0.34M, compared to the prior year. However, the cost of sales for this segment increased by 23% for the three months ended March 31, 2025, largely due to selling a higher volume of lower margin products.

The company's cash position as of June 30, 2025, stood at $11.1M, which management expects is sufficient to fund operating expenses and capital expenditures into the fourth quarter of calendar year 2026, depending on BayMedica revenues and operating expenses.

Metric	Value (FY Ended June 30, 2025)	Period/Date
BayMedica Segment Sales	$4.9M	Year Ended June 30, 2025
BayMedica Sales Growth YoY	8%	Year Ended June 30, 2025 vs. 2024
BayMedica Sales	$1.26 million	Three Months Ended March 31, 2025
Cash, Cash Equivalents, and Investments	$11.1M	As of June 30, 2025
Cash Runway Expectation	Into Q4 2026	Forward-Looking Estimate
Net Loss	$(8.2M)	Year Ended June 30, 2025

Regulatory submissions (e.g., IND applications) to the FDA and other bodies

For the pharmaceutical pipeline, the channel to market is through regulatory approval. This involves extensive preclinical work to support Investigational New Drug (IND) applications. InMed Pharmaceuticals Inc. announced the successful completion of pharmacokinetic (PK) studies in large animal models for its Alzheimer's disease candidate, INM-901. This data is specifically intended to support the design and planning of first in human clinical trials and preparation for a pre-IND meeting with the FDA.

The company's focus remains on advancing these IND-enabling studies for INM-901.

Licensing and partnership agreements with larger pharmaceutical firms

Partnerships are a key channel for de-risking and advancing the drug candidates. InMed Pharmaceuticals Inc. has secured financing and strategic agreements to support this pipeline development.

• The company entered into definitive agreements for a private placement generating aggregate gross proceeds of approximately $5 million, priced at $2.561 per share, closing around June 25, 2025.
• A Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors Global LP, effective December 13, 2024, allows InMed to sell up to $10 million of common shares over a 36-month period.
• A licensing agreement with EyeCRO grants InMed an exclusive, worldwide license to commercialize cannabinoid formulations using the patented MiDROPS® delivery technology.
• InMed is the named industry partner on an NSERC Alliance grant with UBC (Dr. Ujendra Kumar) to support research on cannabinoid analogs for neurodegenerative diseases.
• The ongoing engagement with Almac Group, since May 2020, focuses on optimizing cannabinoid manufacturing processes to achieve cost-efficient, GMP-grade active pharmaceutical ingredients.

Scientific conferences (e.g., AAIC 2025) for data dissemination to researchers

Disseminating preclinical data is a crucial channel for building scientific credibility and attracting potential pharma partners. InMed Pharmaceuticals Inc. actively presented data at major scientific forums in 2025.

• InMed presented new preclinical data for its Alzheimer's disease drug candidate, INM-901, at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, from July 27-31, 2025.
• The data, presented in a scientific poster, showed that INM-901 demonstrated a significant reduction in inflammatory biomarkers (including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 and NfL) in a dose-dependent manner in a long-term 5xFAD mouse model study.
• The management team also conducted company presentations and one-on-one meetings at the Life Sciences Investor Forum on September 18, 2025.
• A pre-recorded presentation for the H.C. Wainwright 27th Annual Global Investment Conference was made available on demand starting September 5, 2025.

The Senior VP, Preclinical Research and Development, Dr. Eric Hsu, attended the AAIC 2025 event. That's the level of engagement you'd expect for a lead candidate.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Customer Segments

You're looking at the core groups InMed Pharmaceuticals Inc. (INM) targets to drive value from its dual-focus strategy-pharmaceutical development and rare cannabinoid sales. This structure is key to understanding their cash runway and R&D progression.

Pharmaceutical companies seeking to license or acquire drug candidates.

For the pipeline assets like INM-901 (Alzheimer's) and INM-089 (dry AMD), the customer segment is large pharmaceutical or biotech firms capable of funding and executing late-stage clinical trials and commercialization. While specific deal values aren't public for in-licensing deals as of late 2025, InMed Pharmaceuticals has actively engaged in strategic collaborations. For instance, they hold an exclusive, worldwide license from EyeCRO to use the MiDROPS® delivery technology for therapeutic cannabinoid formulations. Furthermore, InMed is a named industry partner in a research collaboration with the University of British Columbia (UBC), supported by an NSERC Alliance grant, focusing on cannabinoid analogs for neurodegenerative diseases.

Patients suffering from Alzheimer's disease and dry Age-related Macular Degeneration.

These represent the ultimate end-users for the pharmaceutical pipeline. INM-901 is positioned as a small-molecule drug candidate for Alzheimer's disease (AD) that targets multiple biological pathways, including demonstrating statistically significant reductions in neuroinflammation markers across various preclinical studies. For dry Age-related Macular Degeneration (AMD), INM-089 is under investigation, with preclinical studies showing neuroprotection. The company is advancing IND-enabling studies for these candidates, which is the necessary step before human trials begin to reach this patient population.

Health and Wellness (H&W) product manufacturers/formulators (BayMedica clients).

This segment provides the immediate, recurring revenue stream supporting the R&D engine. BayMedica, the wholly-owned subsidiary, supplies non-intoxicating rare cannabinoids to the global H&W ingredient markets. This business unit generated sales of $4.9 million for the fiscal year ended June 30, 2025, marking an 8% increase over the fiscal year 2024 sales. The goal for this segment has been to achieve approximately 40 percent gross margins. However, recent quarterly performance shows some fluctuation; revenues for the three months ending September 30, 2025, were $1.1 million, down 11% from the same period last year, which management attributed to pricing adjustments.

Here's a quick look at the recent revenue performance for the BayMedica segment:

Period End Date	Revenue Amount	Year-over-Year Change
June 30, 2025 (FY End)	$4.9 million	+8%
September 30, 2025 (Q1 FY2026)	$1.1 million	-11%

Institutional and individual investors funding the R&D pipeline.

Given the capital-intensive nature of drug development, investors are a critical customer segment providing the necessary working capital. InMed Pharmaceuticals Inc. secured gross proceeds of approximately $5 million in a private placement that closed on June 26, 2025, priced at $2.561 per share. This financing, which involved issuing common shares and investment options, represented a 61% dilution for existing shareholders. As of June 30, 2025, the Company reported cash, cash equivalents, and short-term investments totaling $11.1 million. Management projects this cash position is sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.

The reliance on capital markets is evident in recent financing activities:

• Total cash provided by financing activities for the year ended June 30, 2025, was $12.271 million.
• The June 2025 private placement brought in gross proceeds of about $5 million.
• The cash balance on June 30, 2025, was $11.1 million, up from $6.571 million at the beginning of the fiscal year.

Finance: draft 13-week cash view by Friday.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Cost Structure

You're looking at the core expenses InMed Pharmaceuticals Inc. carried in its fiscal year ending June 30, 2025, which is crucial for understanding where the cash went while advancing the pipeline and running the commercial segment.

The Cost Structure is heavily weighted toward the pharmaceutical development efforts, though the commercial segment's costs are also significant for maintaining operations.

Key Expense Categories for Fiscal Year Ended June 30, 2025

Here's the quick math on the two largest reported operating expense categories for the full fiscal year 2025:

Expense Type	Amount (FY2025)
General and Administrative (G&A) expenses	$6.6M
Research and Development (R&D) expenses	$2.9M

The G&A expenses of $6.6M for the year ended June 30, 2025, represented an increase from $5.8M in the prior year, driven mainly by higher legal expenses and consulting fees. The R&D expenses of $2.9M for the same period were actually a slight decrease from $3.2M in fiscal year 2024, but InMed Pharmaceuticals Inc. expects these to increase significantly as pipeline programs advance, especially into IND-enabling studies.

External Contractor Costs for Preclinical and IND-enabling Studies

Specific, full-year dollar amounts for external contractor costs for preclinical and IND-enabling studies for the entire fiscal year 2025 weren't explicitly broken out in the top-line summaries, but quarterly data shows the variability:

• In the third quarter of fiscal 2025 (ended March 31, 2025), R&D expenses increased due to an increase in external contractors relating to the INM-901 and INM-089 programs.
• Conversely, R&D expenses in the first quarter of fiscal 2025 (ended September 30, 2024) were lower partly due to reduced spending on external contractors compared to the prior year's quarter.

This spend is definitely a variable cost tied directly to the advancement milestones for INM-901 and INM-089.

Manufacturing Costs and Cost of Goods Sold for the BayMedica Segment

For the commercial segment, BayMedica, the focus has been on cost management to improve margins. The segment generated sales of $4.9M for the year ended June 30, 2025.

While the total Cost of Goods Sold (COGS) for the full fiscal year 2025 isn't explicitly stated, we see trends from subsequent periods:

• BayMedica continued to reduce manufacturing costs, leading to improved margins over time.
• For the three months ending September 30, 2025, the Cost of goods sold decreased by 7% compared to the same three months in the prior year, a result of lowering supply chain and manufacturing costs.

The company is definitely working to keep the COGS manageable as it navigates pricing pressures in the rare cannabinoid market.

InMed Pharmaceuticals Inc. (INM) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of InMed Pharmaceuticals Inc. (INM) to see how the company funds its drug development pipeline. Honestly, the story here is a dual one: the steady, albeit modest, income from the commercial side supporting the high-risk, high-reward pharma research.

The primary, current revenue stream comes directly from the BayMedica commercial segment. This segment is InMed Pharmaceuticals Inc.'s supplier of non-intoxicating rare cannabinoids to the health and wellness sector. For the full fiscal year ending June 30, 2025, the company realized sales of $4.9M in this segment. This figure represents an 8% year-over-year increase, or an absolute increase of $0.34M, when compared to the sales from the year ended June 30, 2024. To give you a more granular look at that commercial engine during the fiscal year, here's a snapshot of the revenue performance we saw:

Revenue Component/Period	Financial Amount (USD)	Context/Detail
Total Fiscal Year 2025 Revenue	$4.9M	Sales from BayMedica for the year ended June 30, 2025.
Year-over-Year Revenue Growth (FY2025)	8%	Increase compared to fiscal year 2024 sales.
Q3 Fiscal Year 2025 BayMedica Revenue	$1.26M	Revenue for the three months ended March 31, 2025.
Cash Position (As of June 30, 2025)	$11.1M	Cash, cash equivalents, and short-term investments available.

Beyond the current sales, the structure of InMed Pharmaceuticals Inc.'s business model relies heavily on future, non-guaranteed income streams tied to the success of its pharmaceutical pipeline. This is where the potential for significant, step-change revenue lies, though it carries the inherent risk of clinical failure.

Future potential revenue streams are centered on the drug licensing deals for candidates like INM-901 (for Alzheimer's disease) and INM-089 (for dry Age-related Macular Degeneration). These streams are structured as:

• Future potential milestone payments from achieving clinical or regulatory goals.
• Royalties on net sales should any licensed drug candidate reach commercialization.

Finally, you can't ignore the proceeds from financing activities, which are critical for bridging the gap between BayMedica's revenue and the high cash burn of R&D. These proceeds are essential for extending the operational runway. For instance, the company secured gross proceeds of $2.9M from financing activities that took place in January 2025. The cash position as of June 30, 2025, stood at $11.1M, which management projected would be sufficient to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. The expectation is to seek additional funding through:

• Equity financings.
• Debt financings.
• Other capital sources, including collaborations or strategic transactions.

The company defintely uses the BayMedica cash flow to help support the R&D engine.